FDA Rejects Sanofi-Aventis Drug Application
The FDA issues letters when company applications don’t adequately demonstrate a drug’s safety or efficacy. Sanofi-Aventis didn't say why Multaq, which the company hopes will be a blockbuster, was rejected.
Sanofi-Aventis, the world’s third-largest pharmaceutical company, said it would refile an application for the drug at the beginning of next year. The company is hoping to bolster its case with clinical data from an...
To view the full article, register now.